Thrombospondin‑1 is a prognostic biomarker and is correlated with tumor immune microenvironment in glioblastoma

Qi,Chunxiao; Lei,Lei; Hu,Jinqu; Wang,Gang; Liu,Jiyuan; Ou,Shaowu

doi:10.3892/ol.2020.12283

Thrombospondin‑1 is a prognostic biomarker and is correlated with tumor immune microenvironment in glioblastoma

Authors:
- Chunxiao Qi
- Lei Lei
- Jinqu Hu
- Gang Wang
- Jiyuan Liu
- Shaowu Ou
View Affiliations

Affiliations: Department of Neurosurgery, The First Hospital of China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Rheumatology and Immunology, Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Liaoning 116033, P.R. China
Published online on: November 9, 2020 https://doi.org/10.3892/ol.2020.12283
Article Number: 22
Copyright: © Qi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma (GBM) is the most common malignant brain tumor and the most aggressive type of glioma, characterized by strong invasive potential and rapid recurrence despite severe treatment methods, such as maximal tumor resection followed by chemotherapy and radiotherapy. Thrombospondin‑1 (THBS1) was first discovered in platelets and subsequent studies have indicated its functions in the development of several cancers, including breast cancer, melanoma, gastric cancer, cervical cancer and GBM. However, to the best of our knowledge, the expression profiles of THBS1 in GBM subtypes remain unknown, and the underlying mechanism by which THBS1 expression is regulated, and its effect on the local immune response in GBM, remains unclear. The present study used public datasets from The Cancer Genome Atlas, the Chinese Glioma Genome Atlas, the Gene Expression Omnibus, the Ivy Glioblastoma Atlas Project, Tumor Immune Estimation Resource, Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data and the Human Protein Atlas to investigate the prognostic value of THBS1 and its expression profiles, as well as its correlation with the local immune response in GBM. The results demonstrated that THBS1 was a biomarker of the pathological malignancy of glioma, and predicted the mesenchymal subtype of GBM. Furthermore, DNA methylation of THBS1 may be an important mechanism by which THBS1 expression is regulated in GBM. The hypomethylation or overexpression of THBS1 predicted an unfavorable prognosis in patients with GBM. Additionally, THBS1 was correlated with immune and inflammatory responses in GBM. Thus, the findings of the present study provide insight into the potential value of THBS1 in the treatment of GBM.

View Figures

View References

1	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 world health organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
2	Jaoude DA, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E and Moore DF Jr: Glioblastoma and increased survival with longer chemotherapy duration. Kans J Med. 12:65–69. 2019. View Article : Google Scholar : PubMed/NCBI
3	Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, Miller CR, Ding L, Golub T, Mesirov JP, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 17:98–110. 2010. View Article : Google Scholar : PubMed/NCBI
4	Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, et al: Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment. Cancer Cell. 32:42–56.e6. 2017. View Article : Google Scholar : PubMed/NCBI
5	Gill BJ, Pisapia DJ, Malone HR, Goldstein H, Lei L, Sonabend A, Yun J, Samanamud J, Sims JS, Banu M, et al: MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma. Proc Natl Acad Sci USA. 111:12550–12555. 2014. View Article : Google Scholar : PubMed/NCBI
6	Curry JM, Sprandio J, Cognetti D, Luginbuhl A, Bar-ad V, Pribitkin E and Tuluc M: Tumor microenvironment in head and neck squamous cell carcinoma. Semin Oncol. 41:217–234. 2014. View Article : Google Scholar : PubMed/NCBI
7	Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA, et al: Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 4:26122013. View Article : Google Scholar : PubMed/NCBI
8	Hanahan D and Coussens LM: Accessories to the crime: Functions of cells recruited to the tumor microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
9	Jia D, Li S, Li D, Xue H, Yang D and Liu Y: Mining TCGA database for genes of prognostic value in glioblastoma microenvironment. Aging (Albany NY). 10:592–605. 2018. View Article : Google Scholar : PubMed/NCBI
10	Martinez-Lage M, Lynch TM, Bi Y, Cocito C, Way GP, Pal S, Haller J, Yan RE, Ziober A, Nguyen A, et al: Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathol Commun. 7:2032019. View Article : Google Scholar : PubMed/NCBI
11	Miyata Y and Sakai H: Thrombospondin-1 in urological cancer: Pathological role, clinical significance, and therapeutic prospects. Int J Mol Sci. 14:12249–12272. 2013. View Article : Google Scholar : PubMed/NCBI
12	Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, Kumar S and Bundred NJ: Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol. 31:1127–1132. 2007.PubMed/NCBI
13	Nakao T, Kurita N, Komatsu M, Yoshikawa K, Iwata T, Utsunomiya T and Shimada M: Expression of thrombospondin-1 and Ski are prognostic factors in advanced gastric cancer. Int J Clin Oncol. 16:145–152. 2011. View Article : Google Scholar : PubMed/NCBI
14	Trotter MJ, Colwell R and Tron VA: Thrombospondin-1 and cutaneous melanoma. J Cutan Med Surg. 7:136–141. 2003. View Article : Google Scholar : PubMed/NCBI
15	Wu MP, Tzeng CC, Wu LW, Huang KF and Chou CY: Thrombospondin-1 acts as a fence to inhibit angiogenesis that occurs during cervical carcinogenesis. Cancer J. 10:27–32. 2004. View Article : Google Scholar : PubMed/NCBI
16	Zhang J, Yang W, Zhao D, Han Y, Liu B, Zhao H, Wang H, Zhang Q and Xu G: Correlation between TSP-1, TGF-β and PPAR-γ expression levels and glioma microvascular density. Oncol Lett. 7:95–100. 2014. View Article : Google Scholar : PubMed/NCBI
17	Tenan M, Fulci G, Albertoni M, Diserens AC, Hamou MF, El Atifi-Borel M, Feige JJ, Pepper MS and Van Meir EG: Thrombospondin-1 is downregulated by anoxia and suppresses tumorigenicity of human glioblastoma cells. J Exp Med. 191:1789–1798. 2000. View Article : Google Scholar : PubMed/NCBI
18	Kragh M, Quistorff B, Tenan M, Van Meir EG and Kristjansen PE: Overexpression of thrombospondin-1 reduces growth and vascular index but not perfusion in glioblastoma. Cancer Res. 62:1191–1195. 2002.PubMed/NCBI
19	Zhang HP, Wu Y, Liu J, Jiang J, Geng XR, Yang G, Mo L, Liu ZQ, Liu ZG and Yang PC: TSP1-producing B cells show immune regulatory property and suppress allergy-related mucosal inflammation. Sci Rep. 3:33452013. View Article : Google Scholar : PubMed/NCBI
20	de Fraipont F, Keramidas M, El Atifi M, Chambaz EM, Berger F and Feige JJ: Expression of the thrombospondin 1 fragment 167–569 in C6 glioma cells stimulates tumorigenicity despite reduced neovascularization. Oncogene. 23:3642–3649. 2004. View Article : Google Scholar : PubMed/NCBI
21	Daubon T, Léon C, Clarke K, Andrique L, Salabert L, Darbo E, Pineau R, Guérit S, Maitre M, Dedieu S, et al: Deciphering the complex role of thrombospondin-1 in glioblastoma development. Nat Commun. 10:11462019. View Article : Google Scholar : PubMed/NCBI
22	Ma Y, Qu B, Xia X, Yang L, Kuang Y, Yang T, Cheng J, Sun H, Fan K and Gu J: Glioma-derived thrombospondin-1 modulates cd14+ cell tolerogenic properties. Cancer Invest. 33:152–157. 2015. View Article : Google Scholar : PubMed/NCBI
23	Cancer Genome Atlas Research Network, . Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar : PubMed/NCBI
24	Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al: Towards a knowledge-based Human Protein Atlas. Nat Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar : PubMed/NCBI
25	Bowman RL, Wang Q, Carro A, Verhaak RG and Squatrito M: GlioVis data portal for visualization and analysis of brain tumor expression datasets. Neuro Oncol. 19:139–141. 2017. View Article : Google Scholar : PubMed/NCBI
26	Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, et al: T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 11:R152009. View Article : Google Scholar : PubMed/NCBI
27	Wang ZL, Li GZ, Wang QW, Bao ZS, Wang Z, Zhang CB and Jiang T: PD-L2 expression is correlated with the molecular and clinical features of glioma, and acts as an unfavorable prognostic factor. Oncoimmunology. 8:e15415352019. View Article : Google Scholar : PubMed/NCBI
28	Zhou Y, Wang X, Huang X, Li XD, Cheng K, Yu H, Zhou YJ, Lv P and Jiang XB: High expression of COPB2 predicts adverse outcomes: A potential therapeutic target for glioma. CNS Neurosci Ther. 26:309–318. 2019. View Article : Google Scholar : PubMed/NCBI
29	Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B and Liu XS: TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 77:e108–e110. 2017. View Article : Google Scholar : PubMed/NCBI
30	Yi L, Tong L, Li T, Hai L, Abeysekera IR, Tao Z, Ma H, Liu P, Xie Y, Li J, et al: Bioinformatic analyses reveal the key pathways and genes in the CXCR4 mediated mesenchymal subtype of glioblastoma. Mol Med Rep. 18:741–748. 2018.PubMed/NCBI
31	Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AWM, Lu C, Ward PS, et al: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature. 483:479–483. 2012. View Article : Google Scholar : PubMed/NCBI
32	Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C and von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 116:597–602. 2008. View Article : Google Scholar : PubMed/NCBI
33	Razavi SM, Lee KE, Jin BE, Aujla PS, Gholamin S and Li G: Immune evasion strategies of glioblastoma. Front Surg. 3:112016. View Article : Google Scholar : PubMed/NCBI
34	Pan JH, Zhou H, Cooper L, Huang JL, Zhu SB, Zhao XX, Ding H, Pan YL and Rong L: LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front Immunol. 10:62019. View Article : Google Scholar : PubMed/NCBI
35	Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T and Wu A: Tumor purity as an underlying key factor in glioma. Clin Cancer Res. 23:6279–6291. 2017. View Article : Google Scholar : PubMed/NCBI
36	Wu LM, Zhang F, Zhou L, Yang Z, Xie HY and Zheng SS: Predictive value of CpG island methylator phenotype for tumor recurrence in hepatitis B virus-associated hepatocellular carcinoma following liver transplantation. BMC Cancer. 10:3992010. View Article : Google Scholar : PubMed/NCBI
37	Strathdee G, Appleton K, Illand M, Millan DW, Sargent J, Paul J and Brown R: Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am J Pathol. 158:1121–1127. 2001. View Article : Google Scholar : PubMed/NCBI
38	Doucette T, Rao G, Rao A, Shen L, Aldape K, Wei J, Dziurzynski K, Gilbert M and Heimberger AB: Immune heterogeneity of glioblastoma subtypes: Extrapolation from the cancer genome atlas. Cancer Immunol Res. 1:112–122. 2013. View Article : Google Scholar : PubMed/NCBI